Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study).

Next Previous
Trial Profile

The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary)
  • Indications Ischaemic stroke; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms SPAD

Most Recent Events

  • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 15 Aug 2012 Additional lead trial centers identified as reported by ClinicalTrials.gov.
  • 15 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top